Get the Stockscreener App
2.765
11.79%
0.305
Larimar Therapeutics Inc stock is traded at $2.765, with a volume of 767.74K.
It is up +11.79% in the last 24 hours and up +30.95% over the past month.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
See More
Previous Close:
$2.46
Open:
$2.51
24h Volume:
767.74K
Relative Volume:
0.69
Market Cap:
$176.40M
Revenue:
-
Net Income/Loss:
$-36.95M
P/E Ratio:
-3.2917
EPS:
-0.84
Net Cash Flow:
$-33.46M
1W Performance:
+22.22%
1M Performance:
+30.95%
6M Performance:
-57.43%
1Y Performance:
-71.05%
1-Day Range:
$2.47
$2.765
1-Week Range:
$2.12
$2.765
52-Week Range:
$1.61
$11.20
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Name
Larimar Therapeutics Inc
Sector
Industry
Phone
844-511-9056
Address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
2.755 | 147.26M | 0 | -36.95M | -33.46M | -0.84 |
|
ONC
Beone Medicines Ltd Adr
|
256.46 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.71 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2213 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.78 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
496.66 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Initiated | Truist | Buy |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Oct-03-24 | Initiated | Wedbush | Outperform |
| Oct-02-24 | Initiated | H.C. Wainwright | Buy |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Apr-03-24 | Initiated | Leerink Partners | Outperform |
| Nov-17-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-19-22 | Initiated | Guggenheim | Buy |
| Feb-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-10-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-01-21 | Initiated | William Blair | Outperform |
View All
Larimar Therapeutics Inc Stock (LRMR) Latest News
ProShare Advisors LLC Purchases Shares of 14,870 Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Larimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside Potential - MSN
Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock By Investing.com - Investing.com South Africa
Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock - Investing.com
Traws Pharma Highlights Q1 2025 Financial Progress and Antiviral Developments - MyChesCo
Larimar Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MSN
Larimar Therapeutics Advances Nomlabofusp Amid Financial Loss - TipRanks
Larimar Therapeutics Inc (NASDAQ: LRMR): Can A Stock Be -26.10% Lower Year-To-Date And Still Be A Loser? - Marketing Sentinel
The time has not yet come to remove your chips from the table: Larimar Therapeutics Inc (LRMR) - Sete News
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Humana (HUM) and Larimar Therapeutics (LRMR) - The Globe and Mail
Stock Traders Buy High Volume of Call Options on Larimar Therapeutics (NASDAQ:LRMR) - Defense World
LRMR: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Larimar Therapeutics Inc (LRMR)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com
Larimar: Q1 Earnings Snapshot - MySA
Larimar Therapeutics, Inc. SEC 10-Q Report - TradingView
Investor’s Delight: Larimar Therapeutics Inc (LRMR) Closes Strong at 2.39, Up 1.70 - DWinneX
Larimar (LRMR) Advances Clinical Program Towards Potential FDA A - GuruFocus
Investing in Larimar Therapeutics Inc (LRMR) Is Getting More Attractive - knoxdaily.com
Larimar (LRMR) Advances Clinical Program Towards Potential FDA Approval | LRMR Stock News - GuruFocus
Larimar Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewswire
Larimar's Friedreich's Ataxia Drug Gets FDA Accelerated Approval Path While Cash Reserves Surge - Stock Titan
Larimar Therapeutics awards key executives performance-based stock - MSN
Market Watch Highlights: Larimar Therapeutics Inc (LRMR) Ends on an Upturn Note at 2.38 - DWinneX
Larimar Therapeutics Inc (LRMR) Stock: A Comprehensive 52-Week Review - investchronicle.com
Nothing is Better Than Larimar Therapeutics Inc (LRMR) stock at the moment - Sete News
The Potential Rise in the Price of Larimar Therapeutics Inc (LRMR) following insiders activity - knoxdaily.com
Larimar Therapeutics Inc (LRMR)’s results reveal risk - uspostnews.com
Larimar Therapeutics: Initiating Hold Rating With Upcoming Catalysts - Seeking Alpha
An In-Depth Look at Larimar Therapeutics Inc Inc. (LRMR) Price Performance During Market Crashes - investchronicle.com
Larimar to seek accelerated approval of FA therapy nomlabofusp this year - Friedreich's Ataxia News
Q1 EPS Estimate for Larimar Therapeutics Lowered by Analyst - MarketBeat
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth? - Yahoo Finance
Larimar Therapeutics Advances Nomlabofusp Program Amid Regulatory Support - MSN
Larimar Therapeutics (NASDAQ:LRMR) Given Buy Rating at Guggenheim - Defense World
HC Wainwright Issues Positive Forecast for Larimar Therapeutics (NASDAQ:LRMR) Stock Price - Defense World
Larimar Therapeutics Inc (NASDAQ: LRMR) Shares Might Go Down -73.01% This Year - Marketing Sentinel
Larimar Therapeutics (NASDAQ:LRMR) Price Target Cut to $10.00 by Analysts at Robert W. Baird - Defense World
Jones Trading maintains $14 target on Larimar Therapeutics stock By Investing.com - Investing.com UK
Larimar Therapeutics Reports 2024 Financial Results and Development Progress - TipRanks
FDA open to new surrogate endpoint for FA drug approval By Investing.com - Investing.com Australia
Larimar: Q4 Earnings Snapshot - mySA
Wedbush Cuts Price Target on Larimar Therapeutics to $17 From $22, Maintains Outperform Rating - MarketScreener
FDA open to new surrogate endpoint for FA drug approval - Investing.com India
Larimar: Q4 Earnings Snapshot -March 24, 2025 at 07:17 am EDT - MarketScreener
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Breakthrough: FDA Opens Door for Faster Approval of Larimar's Rare Disease Treatment - Stock Titan
Larimar Therapeutics Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Larimar Therapeutics Inc Stock (LRMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.30%
3.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):